- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06665997
Kliniska effekter och biomarköreffekter av depå medroxiprogesteronacetat hos kvinnor med sicklecellssjukdom (SCD Depo)
This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease.
Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Arden McAllister, MPH
- Telefonnummer: 267-785-8044
- E-post: arden.mcallister@pennmedicine.upenn.edu
Studieorter
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Har inte rekryterat ännu
- Emory University
-
Kontakt:
- Hailly Butler
- Telefonnummer: 404-712-8895
- E-post: hailly.butler@emory.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Rekrytering
- Children's Hospital of Philadelphia
-
Kontakt:
- Kandace Gollomp
- Telefonnummer: 215-590-3535
- E-post: gollompk@chop.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Female, aged 18-50 years old
- Diagnosis of sickle cell disease (SS, SB0,SB+,SC)
- Report of at least 1 vaso-occlusive pain episode per month on average in the previous 6 months
- At least 1 and no more than 10 medical presentations (e.g. hospitalization, emergencyroom visit, outpatient infusion visit) for vaso-occlusive pain during the past year, unless approved by study PI Andrea Roe
- Willing to discontinue any hormonal contraception at the time of enrollment. Washout period of 1 month since last use of all hormonal contraception, and 4 months since most recent administration of depot medroxyprogesterone, is required prior to enrollment in the study.
- Have regular menstrual cycles (when not on hormonal contraception) with a usual length of 21 to 35 days.
- Stable dose of hydroxyurea and other sickle cell-related medications for the past 6 months
- Access to a device with text-messaging capability
- Must be able to read and understand English
- Willing to comply with study procedures
Exclusion Criteria:
- Chronic inflammatory conditions, such as lupus or inflammatory bowel disease
- History of VTE or stroke
- Current use of crizanlizumab, voxelotor, or chronic transfusion therapy, including simple transfusion and red cell exchange transfusion, history of hematopoietic stem cell transplantation
- Current use of hormonal contraception or the copper intrauterine device
- Current pregnancy or pregnancy within the last 6 months
- Current lactation
- Polycystic ovary syndrome or irregular periods
- Blood pressure >= 160 systolic or >=100 diastolic at screening visit
- Has a history or current evidence of any condition, therapy, or other circumstance that in the opinion of the investigator exposes the participant to risk through participating in the trial, may confound the results of the trial, or could interfere with participation for the full duration of the trial.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Depot Medroxyprogesterone Acetate (Depo-Provera)
All participants will receive a 150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension after a 3-month baseline with no hormonal contraception. |
150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Frequency of acute vaso-occlusive episodes
Tidsram: 6 months
|
The primary outcome is frequency of VOEs during each phase (baseline and intervention). A VOE is self-reported by the participant. During both the baseline and intervention study phases, participants will provide weekly reports via electronic survey of vaso-occlusive pain. VOE will be defined as self-reported typical SCD pain that interferes with usual daily activities or requires emergency care or hospitalization, with distinct episodes separated by at least one week without pain. |
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
C-reactive protein
Tidsram: 6 months
|
C-reactive protein will be measured from blood samples drawn twice, once during each study phase (baseline and intervention). |
6 months
|
|
Hemoglobin
Tidsram: 6 months
|
Hemoglobin will be measured from blood samples drawn twice, once during each study phase (baseline and intervention). |
6 months
|
|
Reticulocyte count
Tidsram: 6 months
|
Reticulocyte count will be measured from blood samples drawn twice, once during each study phase (baseline and intervention). |
6 months
|
|
Platelet count
Tidsram: 6 months
|
Platelet count will be measured from blood samples drawn twice, once during each study phase (baseline and intervention). |
6 months
|
|
Fetal hemoglobin
Tidsram: 6 months
|
Fetal hemoglobin will be measured from blood samples drawn twice, once during each study phase (baseline and intervention). |
6 months
|
|
Bilirubin
Tidsram: 6 months
|
Bilirubin will be measured from blood samples drawn twice, once during each study phase (baseline and intervention). |
6 months
|
|
D-dimer
Tidsram: 6 months
|
D-dimer will be measured from blood samples drawn twice, once during each study phase (baseline and intervention). |
6 months
|
|
von Willebrand factor
Tidsram: 6 months
|
von Willebrand factor will be measured from blood samples drawn twice, once during each study phase (baseline and intervention). |
6 months
|
|
Pain intensity
Tidsram: 6 months
|
Pain intensity, as measured by the PROMIS Pain Intensity 1a Numeric Rating Scale, comparing baseline and intervention phases. |
6 months
|
|
Pain intensity
Tidsram: 6 months
|
Pain intensity, as measured by the PROMIS Pain Intensity 3a scale, comparing baseline and intervention phases. |
6 months
|
|
Pain interference
Tidsram: 6 months
|
PROMIS pain interference 8a scale, comparing baseline and intervention phases. |
6 months
|
|
Number of vaso-occlusive pain days
Tidsram: 6 months
|
Number of vaso-occlusive pain days as measured in the study diary, comparing baseline and intervention phases. |
6 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Andrea Roe, MD MPH, University of Pennsylvania
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 857039
- 1R01HL175726-01 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
After the study is completed, the de-identified, archived data will be transmitted to the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) for use by other researchers including those outside of the study.
Tidsram för IPD-delning
Data will be made available starting 6 months after publication. There is no planned end date.
Kriterier för IPD Sharing Access
Researchers will obtain access through NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) in accordance with their SOPs.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .